Status:
RECRUITING
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of ...
Detailed Description
This is a non-interventional, national, multicenter prospective and retrospective observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the t...
Eligibility Criteria
Inclusion
- Age equal to or greater than 18 years old at the time of SVd initiation
- Signed informed consent (if applicable).
- Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
- Relapse after one to three lines of therapy.
- Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization)
- Prior treatment with and refractoriness to lenalidomide.
Exclusion
- \- Previous exposure to selinexor.
Key Trial Info
Start Date :
August 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT06933277
Start Date
August 29 2025
End Date
August 1 2028
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aou Careggi - Sod Ematologia
Florence, Italy